PTH(1-34) Analog (Generic Teriparatide)
Muscle/RecoveryPTH fragment / research or compoundedExperimental
PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
For research use only.
Key Facts
- CAS
- 52232-67-4
- Molecular Weight (MW)
- ≈4118 g/mol
- Half-life
- ~1 h (sc); same as Forteo reference
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- PTH1 receptor
Overview
PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
Protocol
- Dosage Range
- Per local label or research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Intermittent PTH1-receptor activation is anabolic to bone; continuous exposure is catabolic. Approved teriparatide is 20 mcg SC daily for up to 2 years.
Targets
PTH1 receptor
Studies
- Teriparatide fracture prevention— Journal/year not available
Benefits
Same class as labeled osteoanabolic therapy
Potential Side Effects
- Hypercalcemia
- Orthostasis
- Leg cramps
References
- PMID 11794169External link · Year —